Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States.

While in the overall trial there was a nonsignificant trend toward reduced total mortality with IPE, in REDUCE‐IT USA, there was a statistically and clinically significant 30% relative and 2.6% absolute risk reduction in total mortality (from 9.8% to 7.2%; hazard ratio [HR], 0.70 [95% CI, 0.55–0.90]; P =0.004).

also in 5,406 other papers